1. Home
  2. HFFG vs SPRO Comparison

HFFG vs SPRO Comparison

Compare HFFG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HF Foods Group Inc.

HFFG

HF Foods Group Inc.

HOLD

Current Price

$2.17

Market Cap

127.8M

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.33

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HFFG
SPRO
Founded
1997
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Food Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
127.8M
136.7M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
HFFG
SPRO
Price
$2.17
$2.33
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
106.0K
258.7K
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,225,541,000.00
$40,549,000.00
Revenue This Year
$4.36
N/A
Revenue Next Year
$3.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.10
N/A
52 Week Low
$1.70
$0.51
52 Week High
$4.93
$3.22

Technical Indicators

Market Signals
Indicator
HFFG
SPRO
Relative Strength Index (RSI) 36.65 50.36
Support Level $2.16 $2.26
Resistance Level $2.29 $2.37
Average True Range (ATR) 0.12 0.07
MACD -0.04 0.00
Stochastic Oscillator 12.17 42.42

Price Performance

Historical Comparison
HFFG
SPRO

About HFFG HF Foods Group Inc.

HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: